ABBOTT LABORATORIES (ABT) Stock Analyst Ratings
USA • New York Stock Exchange • NYSE:ABT • US0028241000
110.83 USD
+1.75 (+1.6%)
At close: Feb 6, 2026
110.45 USD
-0.38 (-0.34%)
After Hours: 2/6/2026, 8:16:38 PM
ChartMill assigns a Buy % Consensus number of 79% to ABT. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 136.02. This target is 22.73% above the current price.
- ABT was analyzed by 35 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ABT.
- In the previous month the buy percentage consensus was at a similar level.
- ABT was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-02 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-23 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-23 | BTIG | Maintains | Buy -> Buy |
| 2026-01-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-23 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-20 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-10-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-16 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-10 | Benchmark | Initiate | Buy |
| 2025-10-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-18 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-07-18 | BTIG | Maintains | Buy -> Buy |
| 2025-07-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-18 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-07-18 | Jefferies | Upgrade | Hold -> Buy |
| 2025-07-16 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-07-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-04-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-04-17 | Stifel | Maintains | Buy -> Buy |
ABBOTT LABORATORIES / ABT FAQ
Can you provide the average price target for ABBOTT LABORATORIES stock?
35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 22.73% is expected in the next year compared to the current price of 110.83.
What is the consensus rating for ABT stock?
The consensus rating for ABBOTT LABORATORIES (ABT) is 79.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ABBOTT LABORATORIES (ABT) stock?
The number of analysts covering ABBOTT LABORATORIES (ABT) is 35.